Our Division

Leadership

Dr. Daniel Kuritzkes has served as our Division Chief since January 2012.  Dr. Kuritzkes had previously served as the Associate Division Chief under Dr. Elliott Kieff. Dr. Kuritzkes is a Professor of Medicine and current Chair of the national AIDS Clinical Trials Group Network, an N.I.H. funded international network that conducts clinical trials of novel therapeutics in HIV/AIDS, tuberculosis, and viral hepatitis. Dr. Kuritzkes also directs the Partners/Harvard AIDS Clinical Trials Unit and the Harvard Center for AIDS Research Program in HIV Therapeutics. 

Dr. Paul Sax is the Division’s Medical Director. Dr. Sax directs the BWH HIV program, and is an internationally recognized expert in HIV clinical care. Besides his clinical leadership roles, Dr. Sax is the course director for the HMS rotation in infectious diseases and for two HMS postgraduate courses.

Dr. James Maguire returned to the BWH in 2008 after a brief interval with the CDC, as a Master Clinician and Teacher in Infectious Diseases. He is an international expert in parasitology and tropical medicine.

Dr. Lindsey Baden is Director of the BWH/DFCI Infectious Diseases Immune-Compromised Host inpatient and outpatient consultative services and also serves as the Division's Director of Clinical Research.

Drs. Richard Platt and Deborah Yokoe co-direct the BWH and DFCI hospital epidemiology programs, study the prevention of morbidity from infection and antimicrobial use in the BWH, DFCI, and HVMA network, and oversee Dr. Thomas O’Brien’s group in WHONET international surveillance of antibiotic resistance. Dr. Yokoe serves as the hospital epidemiologist for BWH and DFCI and Dr. Michael Klompas serves as Associate Hospital Epidemiologist.

Major Areas of Focus

Please visit the "Our Research" page in order to learn more about the division's research projects.  

Recent Press
Recent Accomplishments
  • Demonstrated HIV-1 relapse in recipients of allogeneic stem cell transplantation despite absence of detectable HIV-1 in peripheral blood cells or rectal mucosa
  • Helped craft the hospital’s response to potential cases of Ebola Virus Disease
  • Demonstrated the safety and acceptability of the AccuCirc device for early infant male circumcision in Botswana
  • Identified predictors of suboptimal CD4 response among women receiving suppressive antiretroviral therapy for HIV-1 infection in Africa
  • Developed the use of nanostructured optical photonic crystal biosensor for HIV viral load measurement
  • Demonstrated that vaccine-induced HIV-specific T-cell responses are associated with modest but transient effects on residual HIV viremia in infected persons on antiretroviral therapy, suggesting that induction of more potent immune responses are needed to reduce the HIV reservoir.
  • Identified distinct susceptibilities of corneal Pseudomonas aeruginosa clinical isolates to neutrophil extracellular trap-mediated immunity
  • Demonstrated the effectiveness of spontaneous awakening and spontaneous breathing trials in preventing ventilator-associated pneumonia
  • Characterized the incidence and risk factors for herpes zoster following heart transplantation
  • Demonstrated that detection of exhaled volatile metabolites of Aspergillus fumigates in breath can be used as a novel, noninvasive, pathogen-specific approach to identifying the precise microbial cause of pneumonia
  • Developed guidelines for the prevention and treatment of hepatitis B virus reactivation during immunosuppressive therapy
  • Demonstrated that cefepime has a similar efficacy as carbapenems for the treatment of Enterobacterspecies bacteremia.
  • Evaluated the safety and immunogenicity of a hexon chimeric adenovirus vector expressing HIV-1 Env as a candidate AIDS vaccine
  • Showed that intramuscular administration of an Adenovirus 26-vectored HIV-1 Env vaccine elicits both systemic and mucosal immune responses in humans without mucosal immune activation.
  • Delineated the genomic  landscape of NF-κB in lymphoblastoid cells, highlighting the importance of FOXM1 as a coactivator of NF-κB target gene transcription
  • Demonstrated that microbiota-driven immune cellular maturation is essential for antibody-mediated adaptive immunity to Staphylococcus aureus infection in the eye
  • Showed that the virulence of V. parahaemolyticus is not dependent upon VopC-mediated invasion, consistent with the traditional view that this organism is an extracellular pathogen.
  • Demonstrated that VopV-mediated "effacement" of microvilli enables V. parahaemolyticus to adhere to host cells, suggesting that remodeling of the epithelial brush border is a critical step in pathogenesis.
Future Directions
  • Initiate a high-resolution anoscopy clinic for HIV infected patients.
  • In transplant and oncology infectious diseases, improve systems within the hospital to better facilitate clinical research, learning, and administration. Continue to grow our ambulatory practice to accommodate increased demand at the Dana-Farber Cancer Institute site.
  • Complete the clinical validation of the breath analysis platform for the diagnosis of invasive fungal disease.
  • Establish a Vaccine Response Research Platform to understand the efficacy of different vaccination strategies in cancer and transplantation recipients.
  • Consolidate the team’s leadership in the conduct of clinical trials in immunocompromised hosts and develop a new unit for the study of antimicrobial strategies for multi-drug-resistant bacterial diseases (“superbugs”).
  • Expand studies of HIV-1 persistence in a cohort of infected patients who have undergone myeloablation and allogeneic bone marrow transplantation for malignancies.
  • Initiate pilot clinical trials of investigational approaches to eliminating the HIV reservoir in latently infected cells.

  • Apply functional MRI and SPECT scanning to study effects of antiretroviral drugs with known CNS side effects.

  • Develop educational programs for broad-based education and care in resource limited settings.

  • Better understand the fundamental processes underlying Kaposi’s sarcoma herpesvirus (HHV-8) latent infection.
  • Develop a laboratory-based research program in fungal pathogenesis.

  • Better define the fundamental cell biology of mycobacteria and targets for new antibiotics.

  • Understand community, population, and social dynamics within the human intestinal microbiota.

  • Understand how enteric pathogens interact with gut microbes at the site of the infection.

  • Improve the pipeline for development of low-cost point-of-care diagnostics for TB, HIV, and other infections.

  • Determine the mechanism by which bacterial glycosaminoglycan-binding determines infection outcome.

  • Develop approaches to prevent/treat infections by interfering with glycosaminoglycan-binding.

  • Raise endowment funds to improve research opportunities.

LEARN MORE ABOUT BRIGHAM AND WOMEN’S HOSPITAL


For over a century, a leader in patient care, medical education and research, with expertise in virtually every specialty of medicine and surgery.

About BWH